Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Critical Therapeutics said that trials of anti-inflammatory compound CTI-01 failed to meet its primary endpoint of reducing major complications 14 to 28 days after major surgery.
Subscribe to our email newsletter
The company said that it plans to assess whether there is an opportunity to continue development of CTI-01 with a collaborative partner or to out-license the drug. Critical Therapeutics licensed patent rights related to CTI-01 from the University of Pittsburgh and Xanthus Pharmaceuticals.
The results from this double-blind, placebo-controlled trial covered the 102 patients enrolled in the trial prior to March 15, 2006 when the company discontinued the trial due to a manufacturing issue related to the drug container closure system.